Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis - ABATACEPT-AS-01

Charité University Medicine0 个研究点目标入组 30 人开始时间: 2007年8月24日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Only patients with moderate to severe ankylosing spondylitis will be included. This implies that only patients with radiological evidence of sacroiliitis (fulfilling the modified New York criteria for AS) will be included.
•1) Patients 18- 65 years of age who have moderate to severe ankylosing spondylitis.
•Group 1: TNFalpha inhibitor naïve patients: active AS patients with inadequate response to conventional therapy (e.g. NSAIDs, glucocorticosteroids or DMARDs) or with intolerance of conventional therapy.
•Group 2: TNFalpha inhibitor failures: active AS patients with inadaequate response to treatment with TNFalpha inhibitors (= patients with previous treatment with TNFalpha inhibitors who showed an inadaquate response according to the international ASAS recommendations; NOT AS patients who had to discontinue TNFalpha inhibitor treatment because of intolerance)
•3) active disease is defined as a BASDAI score of >= 4, back pain score (BASDAI question 2) of >= 4 despite concurrent NSAID therapy, or intolerance to NSAIDs (first group) or prior treatment with TNFalpha inhibitors (second group)
•4) if on NSAIDs, dosage must be stable 2 weeks prior to baseline. During the study dosage should be stable but is allowed to be reduced if documentated.
•5) If on prednisone, <=10.0 mg per day, must be stable for 4 weeks prior to baseline and should be kept stable during the study
•6) If on sulfasalazine or methotrexate, must be stable for 4 weeks prior to baseline
•7) If on TNFalpha blocking agent (infliximab, etancercept, adalimumab), the TNFalpha-blocking therapy must have been terminated at least 4 weeks prior to baseline if etanercept was used and at least 8 weeks if infliximab or adalimumab were used.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1) Current clinical or laboratory evidence of active or latent tuberculosis (TB) and subjects with a history of active TB treated within the last 3 years --> all potential subjects will have a screening chest x-ray at baseline (acceptable if present within the last 3 months); all potential subjects will have a Tuberculin skin test at screening
•2) Patients with other chronic inflammatory articular disease or systemic autoimmune disease, e.g. Systemic lupus erythematosus, Sjögren’s syndrome, active rheumatoid vasculitis, a history of systemic diseases associated with arthritis, chronic fatigue syndrome (other manifestations of spondyloarthritis such as psoriasis, inflammatory bowel disease, arthritis, uveitis are not regarded as exclusion criteria)
•3) Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms
•4) Hepatitis B or C or HIV
•5) Primary or secondary immunodeficiency.
•6) History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised
•7) A history of pulmonary or cardiac insufficiency, or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome
•8) Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease ( e.g. heart failure class III/IV NYHA, cardiac infarct within last 6 month)
•9) nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders
•10) Neuropathy that can interfere with quality of life and/or pain assessment.
•11) Patients with a history of a severe psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
•12) History of current evidence of abuse of hard” drugs (e.g. cocaine/ heroine) oralcoholism
•13) Known hypersensitivity to any component of the study medication
•14) Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test (urine test)
•15) Males or females of reproductive potential not willing to use effective contraception (e.g. contraceptive pill, IUD, physical barrier)
•16) History of alcohol, drug or chemical abuse within 6 month prior to screening
•Exclusion criteria related to medications:
•1) if previously on TNFalpha blocking agents, discontinuation of TNFalpha-blocking agents because of intolerance.
•2) If on leflunomide, leflunomide must have been terminated at least 8 weeks prior to the first abatacept administration (or = 28 days after 11 days of standard cholestyramine or activated charcoal washout).
•3) If on TNFalpha blocking agent (infliximab, etancercept, adalimumab), the TNFalapha therapy must have been terminated at least 4 weeks prior to the first abatacept adminstration if etanercept was used and at least 8 weeks if infliximab or adalimumab were used
•4) Previous treatment with abatacept or rituximab
•5) If on sulfasalazine or methotrexate, must be stable for 4 weeks prior to baseline
•6) Corticosteroids at doses exceeding 10 mg per day of prednisolone or the equivalent within the last 4 weeks prior to the first abatacept administration
•7) Previous treatment with any investigational agent within 28 days ( or less than 5 terminal half-lives of elimination) of day 1 dose
•8) Previous treatment with i.v. immunoglobulins
•9) Receipt of a live vaccine within 4 weeks prior to treatment
•10) Intra-articular or par

研究者

发起方

Charité University Medicine

相似试验

已完成

1 期

An open label, single dose, phase I pilot study to determine the pharmacokinetic, safety and tolerability profiles of oxymorphone delivered from a transdermal oxymorphone patchTo promote pain relief, tested in healthy volunteers.Anaesthesiology - Pain management

ACTRN12613000085774Phosphagenics Limited12

已完成

1 期

An open label, phase I single application study to determine the pharmacokinetic, safety and tolerability profiles of oxycodone delivered from a transdermal oxycodone patch.

ACTRN12613000398707Phosphagenics Limited12

尚未招募

2 期

Evaluation the efficacy of Siddha medicine (Soothaga Mezhugu) for the treatment of Polycystic Ovarian Syndrome.

CTRI/2024/06/068998il

尚未招募

4 期

An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.Opioid-induced ConstipationOral and Gastrointestinal - Normal oral and gastrointestinal development and function

ACTRN12611000002987The Royal Children's Hospital6

进行中（未招募）

1 期

Trial to evaluate the safety and diabetes status in patients with recent-onset Type 1 diabetes by giving GAD-antigen (Diamyd®) therapy into lymph NODEs in combination with an oral Vitamin D regimeType 1 diabetes

EUCTR2014-001417-79-SEinköping University12